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Over the last decade, several studies focused on circulating
nucleic acids as potential cell-cell communication mediators
or as disease biomarkers, thus potentially improving and
extending the strategies to understand and diagnose/prog-
nose many diﬀerent diseases. Particularly, noncoding RNAs
(including microRNAs, piRNAs, and long noncoding RNAs)
received a bulk of attention due to their role as intracellular
regulators of gene expression. Most of the eﬀorts have
focused on microRNAs which are single-stranded small non-
coding RNAs of 19–24 nucleotides in length that negatively
regulate gene expression through their binding to the 3′
untranslated region (UTR) of the messenger RNA (mRNA)
target. MicroRNAs have been demonstrated to be part of
pivotal cellular processes through their ability to posttran-
scriptionally modulate expression levels of many target genes;
consequently, they were associated to the regulation of
important metabolic processes ranging from insulin secre-
tion (pancreatic islet) and insulin sensitivity (muscle, adipose
tissue) to bone deposition and absorption.
It is now well known that microRNAs can be secreted by
virtually every cell type and deploy important functions in
cell-cell and interorgan communication, being found in most
of the extracellular ﬂuids through the associations with sev-
eral circulating components including Argonaute proteins,
HDL particles, microvesicles, and exosomes.
In this Special Issue, authors focused on diﬀerent aspects
of circulating microRNAs’ biology and function in endocrine
and metabolic diseases as well as addressed issues that needs
further clariﬁcation. M. A. C. Pomatto et al. described the
role of extracellular vesicles (EVs) in the transport of circulat-
ing noncoding RNAs and their role in several diseases
including metabolic syndrome, diabetes, thyroid disorders,
preeclampsia, and atherosclerosis. They also discuss the
challenges associated with EV isolation from diﬀerent bio-
logical ﬂuids (serum, plasma, and cell culture media) and
content analysis which could explain the poor technical
and data reproducibility observed between diﬀerent research
groups. The importance of EVs in noncoding RNA trans-
port and interorgan communicationhas been elegantly shown
by Thomou et al. whereby circulating EVs derived from adi-
pose tissue modulate hepatic function/metabolism. Further
addressing the role of microRNA networks in adipose tissue
may help to clarify the entire mechanism by which adipose
tissue regulates the activity of distant organs. To this aim,
Y. O. N. Lopez et al. elucidated the regulatory network exist-
ing between adipose tissue miR-24, miR-146a, and miR-30d
and the antiangiogenic factor secreted frizzled-related pro-
tein 4 (SFRP4) in obesity and type 2 diabetes (T2D). These
microRNAs were found to be upregulated in type 2 diabetes
(T2D) and obese patients compared to healthy controls and
correlated with elevated whole body adiposity and with
SFRP4 levels in visceral adipose tissue, thus supporting the
presence of a regulatory loop between microRNAs and
SFRP4 in obesity and T2D pathophysiology.
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Deciphering interorgan communication by EVs may also
represent a novel pathological component of diﬀerent dis-
eases as observed in gestational diabetes mellitus (GDM) in
which circulating microRNAs derived from placenta EVs
may trigger insulin resistance and beta-cell dysfunction.
Toward this end, E. Guarino et al. now reports on most
recent ﬁndings on exosomes and circulating noncoding
RNAs in GDM and discuss how technical development
may improve the identiﬁcation and characterization of
placenta-derived circulating exosomes.
Additionally, microRNAs have been shown to modu-
late vascular endothelium homeostasis and bonemetabolism.
F. Barutta et al. and M. Materozzi et al. reviewed the current
knowledge on the pathological eﬀect of noncoding RNAs
in microvascular complications in diabetes and bone oste-
oporotic alterations, respectively. Whereas alteration in
microRNA activity may play a crucial role in vascular
complications found in diabetics, these tiny regulatory cir-
culating molecules may represent potential biomarkers of
bone activity as well.
Finally, several ongoing studies are trying to characterize
the potential use of circulating miRNAs as biomarkers of
therapeutic response, in order to anticipate the ﬁnal out-
come. In this special issue, G. Catanzaro et al. explored such
possibility by analyzing circulating miRNAs in plasma of
T2D patients before and after dipeptil dipeptidase IV inhibi-
tor (DPP-IVi) sitagliptin therapy. Analysis of circulating
microRNA proﬁles revealed three microRNAs correlating
with responses to DPP-IVi in those patients: miR-378 which
was associated with a resistance to DPP-IVi and miR-126-3p
and miR-223 which were positively correlated with DPP-IVi
response in T2D patients. This study highlights the potential
usefulness of circulating microRNAs in predicting the
response of patients to glucose-lowering drugs used and
may help contribute to improving personalized medicine in
the near future.
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